Request Trial
steve-debenport-1
steve-debenport-1 / iStockphoto.com
17 May 2018Americas

Illumina and Sequenom take on Ariosa in DNA patent infringement case

Illumina and Sequenom have filed a patent infringement case against Ariosa Diagnostics for a patent covering DNA testing in pregnant women.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US biotech fires trade secrets suit at Chinese pharma group
10 June 2026   Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
Americas
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
8 June 2026   Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

US biotech fires trade secrets suit at Chinese pharma group
Hikma v Amarin: Six takeaways from the pivotal ruling
Exclusive: ‘When a UPC judge wears their robe, they have no gender’
Clarivate’s new IP president to ‘usher in next phase of growth’
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Ex-Kirkland patent litigator jumps to rival firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech